Immunomodulatory News and Research

RSS
Colectomy need in patients with severe ulcerative colitis drastically reduced by Kappaproct

Colectomy need in patients with severe ulcerative colitis drastically reduced by Kappaproct

Preliminary results from Incyte’s INCB024360 Phase I trial on solid tumors

Preliminary results from Incyte’s INCB024360 Phase I trial on solid tumors

EPO issues patent to Cytune’s CYP0150 for treatment of cancer

EPO issues patent to Cytune’s CYP0150 for treatment of cancer

Statin therapy prevents cancer and reduces death risk in heart transplant recipients

Statin therapy prevents cancer and reduces death risk in heart transplant recipients

Galectin Therapeutics commences Phase 1/2 trial of new treatment combination for advanced MM

Galectin Therapeutics commences Phase 1/2 trial of new treatment combination for advanced MM

InDex Pharmaceuticals granted U.S. patent for novel treatment of steroid-resistant inflammation

InDex Pharmaceuticals granted U.S. patent for novel treatment of steroid-resistant inflammation

New genetic signature may predict NSCLC patients at risk of relapse

New genetic signature may predict NSCLC patients at risk of relapse

BfArM grants Moberg Derma approval to initiate Limtop clinical phase I trial for actinic keratosis

BfArM grants Moberg Derma approval to initiate Limtop clinical phase I trial for actinic keratosis

Juvenile arthritis affected kids are at a high risk of cancer: Study

Juvenile arthritis affected kids are at a high risk of cancer: Study

FDA allows marketing of Stratify JCV Antibody ELISA test for PML

FDA allows marketing of Stratify JCV Antibody ELISA test for PML

Researchers present results from 31 major studies of blood-related cancers at ASH 2011 meeting

Researchers present results from 31 major studies of blood-related cancers at ASH 2011 meeting

Galectin Therapeutics to initiate GM-CT-01 Phase 1/2 combination study in advanced MM

Galectin Therapeutics to initiate GM-CT-01 Phase 1/2 combination study in advanced MM

Study reveals mechanism of action of laquinimod in patients with RRMS

Study reveals mechanism of action of laquinimod in patients with RRMS

Compugen's Antibody Target Discovery Platform presented at 7th Annual European Antibody Congress

Compugen's Antibody Target Discovery Platform presented at 7th Annual European Antibody Congress

Celgene to initiate apremilast Phase III placebo-controlled trial for ankylosing spondylitis

Celgene to initiate apremilast Phase III placebo-controlled trial for ankylosing spondylitis

Compugen third quarter net loss decreases to $3.6 million

Compugen third quarter net loss decreases to $3.6 million

Romark announces results from NT-300 Phase 2B-3 trial on influenza

Romark announces results from NT-300 Phase 2B-3 trial on influenza

Xencor commences XmAb5871 Phase 1 trial in autoimmune diseases

Xencor commences XmAb5871 Phase 1 trial in autoimmune diseases

JCO publishes Keryx's KRX-0401 Phase 1 / 2 combination study on advanced MM

JCO publishes Keryx's KRX-0401 Phase 1 / 2 combination study on advanced MM

Scientists demonstrate how Modified Citrus Pectin enhances immune function

Scientists demonstrate how Modified Citrus Pectin enhances immune function

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.